Sensitivity and specificity for each transcript set.

<p>Eight previously published transcript sets were linked to the expression values of 42 RA patients treated with anti-TNF in this study. After k-means cluster analysis the sensitivity and specificity were calculated</p

Cluster analysis for the reported transcript sets.

<p>K-means cluster analysis based upon the transcript sets reported by (A) Lequerré (20 genes) (B) Stuhlmuller (11 genes) (C) Stuhlmuller (82 genes) (D) Lequerré (8 genes) (E) Sekiguchi (18 genes) (F) Julia (8 genes) (G) Stuhlmuller (3 genes) and (H) Tanino (8 genes). The previously published transcript sets were linked to the expression values of 42 RA patients treated with anti-TNF in our study. The two clusters were identified as the non-responder (1) and responder (2) clusters. Profiles are ranked according the results obtained after clustering, in which profile A showed the best results. • = responder; ○ = non-responder.</p

Baseline characteristics, disease activity at baseline and DAS28 improvement for responders and non-responders to anti-TNF treatment.

<p>Results are number (percentage) or mean (SD). Percentages are expressed in relation to the total number of patients for each response group (except for the total number of patients). P-value indicates a significant difference between the two response groups NS: not significant.</p

Effects of prednisolone on glucose kinetics after 21 days of treatment.

<p>(<b>A</b>) Blood glucose concentrations (<b>B</b>) MCR (<b>C</b>) EGP levels MCR (<b>D</b>) C-peptide concentrations (<b>E</b>) C-peptide HOMA-IR. Results represent means ± SD and are outlined for each experimental group (n = 12). * Significant difference p≤0.05, ** significant difference p≤0.01, *** significant difference p≤0.001, ^#significant difference (p≤0.05) when compared to the placebo-treated non-arthritic mice, NS  =  not significant.</p

Effects of prednisolone on bodyweight, thymus weight and arthritis development after 21 days of treatment.

<p>(<b>A</b>) Bodyweight (<b>B</b>) thymus weight (<b>C</b>) AUC of the overall arthritis score (<b>D</b>) X-ray analysis to assess bone destruction. Results are represented as means ± SD for bodyweight and thymus weight and as mean ±SEM for AUC arthritis score and X-ray score and are outlined for each experimental group (n = 12). * Significant difference p≤0.05, ** significant difference p≤0.01, *** significant difference p≤0.001, NS  =  not significant.</p

Effects of ORG 37663 and prednisolone on glucose kinetics after 21 days of treatment.

<p>(<b>A</b>) Blood glucose concentrations (<b>B</b>) MCR (<b>C</b>) EGP levels (<b>D</b>) C-peptide concentrations (<b>E</b>) C-peptide HOMA-IR. Results represent means ± SD and are outlined for each experimental group (n = 12). * Significant difference p≤0.05, ** significant difference p≤0.01, *** significant difference p≤0.001, ^#significant difference (p≤0.05) when compared to the placebo-treated non-arthritic mice, NS  =  not significant.</p

Treatment parameters for both non-arthritic and arthritic mice treated with prednisolone for 21 days.

<p>Both non-arthritic and arthritic mice are treated with prednisolone (0, 1.5, 10 and 30 mg/kg/day) for 21 days. Each experimental group consists of 12 mice; in total 48 non-arthritic and 48 arthritic mice were included. Values represent means ± SD during the blood glucose kinetics test except BW, which is represented as means ± SD before the test.</p><p>* Significant difference (p≤0.05) when compared to the placebo-treated group of that same parameter.</p>#<p>Significant difference (p≤0.05) when compared to the placebo-treated non-arthritic mice.</p><p>Treatment parameters for both non-arthritic and arthritic mice treated with prednisolone for 21 days.</p

Arthritis development.

<p>Arthritis development in mice subjected to blood glucose kinetics three times and in mice in which no experiments were performed. (<b>A</b>) AUC of the overall arthritis score, corrected for base line, after 21 days. (<b>B</b>) X-ray analysis to assess bone destruction. Results are presented as mean ± SEM (n = 20). No significant differences between the two groups was observed. NS  =  not significant.</p

Effects of ORG 37663 and prednisolone on bodyweight, thymus weight and arthritis development after 21 days of treatment.

<p>(<b>A</b>) Bodyweight (<b>B</b>) thymus weight (<b>C</b>) AUC of the overall arthritis score (<b>D</b>) X-ray analysis to assess bone destruction. Results are represented as means ± SD for bodyweight and thymus weight and as mean ±SEM for AUC arthritis score and X-ray score and are outlined for each experimental group (n = 12). * Significant difference p≤0.05, ** significant difference p≤0.01, *** significant difference p≤0.001, ^#significant difference (p≤0.05) when compared to the placebo-treated non-arthritic mice, NS  =  not significant.</p

Treatment parameters for both non-arthritic and arthritic mice treated with placebo, prednisolone (10 mg/kg) or ORG 37663 (12 mg/kg) for 21 days.

<p>Both non-arthritic and arthritic mice are treated with placebo, prednisolone (10 mg/kg/day) or ORG 37663 (12 mg/kg/day) for 21 days. Each experimental group consists of 12 mice; in total 36 non-arthritic and 36 arthritic mice were included. Values represent means ± SD during the blood glucose kinetics test except BW, which is represented as means ± SD before the test.</p><p>* Significant difference (p≤0.05) when compared to the placebo-treated group of that same parameter.</p>#<p>Significant difference (p≤0.05) when compared to the placebo-treated non-arthritic mice.</p><p>Treatment parameters for both non-arthritic and arthritic mice treated with placebo, prednisolone (10 mg/kg) or ORG 37663 (12 mg/kg) for 21 days.</p